(Q38407675)

English

Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements

scientific article published on 31 May 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Andrew R. Lloyd

object named as

Andrew R Lloyd

3

0 references

4

object named as

Gregory J Dore

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

1

object named as

Jason Grebely

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

author name string

Gail V Matthews

2

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

language of work or name

0 references

publication date

31 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Clinical Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

57

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

1014-1020

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Global epidemiology of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Behavioural interventions for preventing hepatitis C infection in people who inject drugs: a global systematic review

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

What is killing people with hepatitis C virus infection?

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Hepatitis C treatment for injection drug users: a review of the available evidence

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Limited uptake of hepatitis C treatment among injection drug users

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

The changing therapeutic landscape for hepatitis C.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Prevention of HIV-1 infection with early antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Treatment of hepatitis C as prevention: a modeling case study in Vietnam

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Mathematical modelling of hepatitis C treatment for injecting drug users

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Optimal control of hepatitis C antiviral treatment programme delivery for prevention amongst a population of injecting drug users

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Can Hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

HIV treatment as prevention: models, data, and questions--towards evidence-based decision-making

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Changes in blood-borne infection risk among injection drug users

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

High hepatitis C incidence in new injecting drug users: a policy failure?

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Elevated rates of HIV infection among young Aboriginal injection drug users in a Canadian setting.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Unstable housing and hepatitis C incidence among injection drug users in a Canadian setting

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

High hepatitis C virus prevalence and incidence among Canadian intravenous drug users

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Availability of body art facilities and body art piercing do not predict hepatitis C acquisition among injection drug users in Montreal, Canada: Results from a cohort study.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Hepatitis C virus infection among injection drug users: survival analysis of time to seroconversion

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Transmission of hepatitis C virus: rates, routes, and cofactors

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Risk for occupational transmission of human immunodeficiency virus type 1 (HIV-1) associated with clinical exposures. A prospective evaluation

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Subtype-specific transmission probabilities for human immunodeficiency virus type 1 among injecting drug users in Bangkok, Thailand

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

A systematic approach to the treatment of HIV and hepatitis C virus infection in the inner city: a Canadian perspective

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Market uptake of new antiviral drugs for the treatment of hepatitis C.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Public health impact of antiviral therapy for hepatitis C in the United States

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Follow-up studies of treatment for hepatitis C virus infection among injection drug users

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Reinfection with hepatitis C virus following sustained virological response in injection drug users

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Prospects for prophylactic and therapeutic vaccines against hepatitis C virus

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Determinants of successful chronic hepatitis C case finding among patients receiving opioid maintenance treatment in a primary care setting

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Successful integration of hepatitis C evaluation and treatment services with methadone maintenance

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Referral for chronic hepatitis C treatment from a drug dependency treatment setting.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Identifying former injecting drug users infected with hepatitis C: an evaluation of a general practice-based case-finding intervention

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Knowledge of and interest in hepatitis C treatment at a methadone clinic

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

[Willing to undergo hepatitis C treatment in a sample of injection drug users in Toronto, Canada].

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Barriers associated with the treatment of hepatitis C virus infection among illicit drug users.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT377

21 January 2018

Identifiers

10.1093/CID/CIT377

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38407675&oldid=1798158134"